Mirvetuximab soravtansine
- Generic Name
- Mirvetuximab soravtansine
- Brand Names
- Elahere
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1453084-37-1
- Unique Ingredient Identifier
- 98DE7VN88D
- Background
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine). DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1.
...
- Indication
Mirvetuximab soravtansine is indicated for the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.
...
- Associated Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Platinum Resistant Primary Peritoneal Cancer, Platinum drug resistant Fallopian tube cancer
- Associated Therapies
- -
Ocular Toxicity Management and Early FRα Testing Are Key to Maximizing Efficacy of ...
Integrating new therapies like mirvetuximab soravtansine-gynx into ovarian cancer care is crucial for improving survival and QOL. Early testing for folate receptor alpha (FRα) expression and specialist collaboration, especially for ocular toxicities, are essential for optimal integration. The FDA approved mirvetuximab soravtansine in 2022 for FRα-positive, platinum-resistant ovarian cancer, supported by phase 3 trials showing OS benefits. Specialist involvement is key for managing AEs, ensuring patient safety and efficacy.
Related Clinical Trials:
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Crinetics Pharmaceuticals appoints Isabel Kalofonos as Chief Commercial Officer to lead commercial strategy for paltusotine, a potential treatment for acromegaly, and pre-commercialization activities for the company's pipeline.
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC
FDA grants Merck's sacituzumab tirumotecan (sac-TMT) breakthrough therapy designation for advanced non-squamous NSCLC with EGFR mutations, post-chemotherapy progression. This marks the first BTD for sac-TMT, an ADC developed with Kelun-Biotech, with Merck holding global marketing rights except in Greater China.
[Reporter's Notebook] Korea's outdated companion diagnostic system limits access to ...
Precision medicine in cancer treatment requires accurate companion diagnostics, but Korea's system lags, recognizing only two biomarkers (PD-L1 and ALK) for IHC tests. This hinders access to new therapies like Enhertu, Vyloy, and Elahere, which target biomarkers not yet covered by the current reimbursement system. The National Evidence-based Healthcare Collaborating Agency's (NECA) review process delays the listing of new biomarkers, creating a cycle that impedes the introduction of new treatments.
Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success
ADCs combine monoclonal antibody precision with cytotoxic drugs, improving efficacy and safety. They selectively target cancer cells, reducing side effects and treating advanced or drug-resistant cancers. ADC technology is advancing with enhanced linker stability, optimized payloads, and the bystander effect, expanding the scope of targetable cancers. Challenges include off-target toxicity, dose optimization, and biomarker identification. ADCs offer potential for personalized oncology therapies, with 15 FDA-approved ADCs as of 2024. Future advancements aim to improve therapeutic indices, reduce toxicity, and enhance combination therapies.
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
The article discusses the use of SSR (Server-Side Rendering) and its implementation through a specific JavaScript file.
ELAHERE Receives EU Approval for Treating Platinum-Resistant Ovarian Cancer
AbbVie's ELAHERE received EC marketing authorization for platinum-resistant ovarian cancer, targeting FRα-positive patients. The approval, supported by MIRASOL Phase 3 trial data, offers a 35% reduction in tumor progression risk and a 33% reduction in death risk. Roche's VENTANA FOLR1 RxDx Assay also received CE Mark approval to identify eligible patients.
AbbVie bags EU nod for key drug from ImmunoGen takeover
AbbVie's $10.1 billion acquisition of ImmunoGen secures EU approval for Elahere, the first drug for FRα-positive, platinum-resistant ovarian cancer. Elahere, an ADC, was approved in the US in 2022 and received full FDA approval in March. The EU approval ends a 10-year treatment hiatus and shows improved overall survival compared to chemotherapy. The MIRASOL trial supports these findings, with a 33% reduction in death risk and 35% improvement in progression-free survival. Rivals include Eisai's farletuzumab ecteribulin, but Elahere is expected to dominate, with potential sales of $2.8 billion by 2029.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath